NeuroBo reports FY2022 net loss $14.0M; cash $33.4M; pipeline shift to cardiometabolic

MetaVia Inc.

Net loss of $14.0M ($5.43 per share) vs $15.3M ($19.81 per share) in FY2021.
Cash and equivalents $33.4M as of Dec 31, 2022, up from $16.4M; runway into 2024.
R&D expenses fell to $2.8M from $6.5M due to reduced clinical activity and drug manufacturing.
Pipeline focus: DA-1241 phase 2a NASH study starts Q3 2023; DA-1726 IND/phase 1a expected H1 2024.
Legacy programs (ANA001, NB-01, NB-02, Gemcabene) to be licensed or acquired.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

MetaVia Inc. reported year ended December 31, 2022 results: net income Net Loss for the year ended December 31, 2022 was $14.0 million, EPS $5.43 per basic and diluted share.

Period: year ended December 31, 2022
Net income: Net Loss for the year ended December 31, 2022 was $14.0 million
EPS: $5.43 per basic and diluted share
Result: reported results

Exact text from the filing

Net Loss for the year ended December 31, 2022 was $14.0 million, or $ 5.43 per basic and diluted share

View on SEC.gov

23 earnings releases filed in the last 30 days. Browse all earnings releases →

MetaVia Inc. filing history →

Source: SEC EDGAR

accession 0001558370-23-005110

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.